Beyond Ozempic: The “Triple G” Mechanism

Retatrutide represents the cutting edge of metabolic medicine. While Semaglutide targets just GLP-1, and Tirzepatide targets GLP-1 and GIP, Retatrutide acts as a triple agonist by also stimulating the Glucagon receptor.

  • GLP-1: Reduces appetite and slows gastric emptying.
  • GIP: Improves insulin secretion and lipid metabolism.
  • Glucagon: Increases energy expenditure (calorie burning) by stimulating the liver to release stored glucose and burn fat.

This third component is crucial. By increasing the metabolic rate, Retatrutide helps overcome the “plateau” effect seen in other treatments.

Scientific References

  • Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine. 2023.
  • Coskun T, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist…” Cell Metabolism. 2022.